SCHEMBL4183076

SCHEMBL4183076

NCc1cc2cccc(Cl)c2nc1N1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
RAB9A P51151 2/20 0.44
PIK3CD O00329 3/20 0.42
TSHR P16473 2/20 0.40
ALOX15 P16050 2/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
CNR2 P34972 3/20 0.40
LMNA P02545 1/20 0.37
FABP3 P05413 1/20 0.37
CYP2C9 P11712 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
PKM P14618 1/20 0.37
PNMT P11086 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13853066 0.80 HPGD (0.39) HPGDSMN1; SMN2RAB9APIK3CDTSHR
SCHEMBL718113 0.78 PRKCH (0.38) PIK3CDPKMKDM4EKMT2AMAPT
SCHEMBL715249 0.77 HPGD (0.43) HPGDSMN1; SMN2RAB9APIK3CDTSHR
SCHEMBL27781347 0.76 HPGD (0.44) HPGDSMN1; SMN2RAB9APIK3CDTSHR
SCHEMBL4171139 0.74 PIK3CD (0.61) HPGDSMN1; SMN2PIK3CDTSHRALOX15
SCHEMBL16793245 0.70 PNMT (0.50) HPGDSMN1; SMN2RAB9AL3MBTL1ALDH1A1
SCHEMBL11591 0.69 PRKCH (0.37) PIK3CDPKMKDM4EKMT2A
SCHEMBL1313748 0.69 PNMT (0.42) HPGDSMN1; SMN2PIK3CDALDH1A1LMNA
SCHEMBL4178087 0.69 DPP4 (0.51) PIK3CDALDH1A1PNMTKDM4E
SCHEMBL718208 0.69 L3MBTL1 (0.60) SMN1; SMN2PIK3CDTSHRALOX15CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2020-02-13 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2018-04-19 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
US-9873701-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2018-01-23 US disclosed
EP-3045458-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2016-07-20 EP disclosed
EP-2137186-B1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2016-01-27 EP disclosed
EP-2137186-B1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2016-01-27 EP disclosed
US-20150045361-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC (US) 2015-02-12 US disclosed
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2012-08-30 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
EP-2137186-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen Inc. (US) 2009-12-30 EP disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed
WO-2008118468-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2008-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048265-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 HPGD 2389/4885SMN1; SMN2 989/4885RAB9A 2240/4885
US-20090137581-A1 Heterocyclic compounds and their uses MCL1, BCL9, MALT1 HPGD 2389/4885SMN1; SMN2 989/4885RAB9A 2240/4885
US-20120220586-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 HPGD 2389/4885SMN1; SMN2 989/4885RAB9A 2240/4885
US-20150045361-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 HPGD 2389/4885SMN1; SMN2 989/4885RAB9A 2240/4885
US-20180105532-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 HPGD 2389/4885SMN1; SMN2 989/4885RAB9A 2240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.